Your AI-Trained Oncology Knowledge Connection!

Frederick Locke, MD

home / authors / frederick-locke-md

Articles

Frederick Locke, MD, Speaks to Clinicians on the Use of Axi-cel in LBCL

April 28th 2022

Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.

Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL

Frederick Locke, MD

April 21st 2022

Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.

Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL

Frederick Locke, MD

April 16th 2022

Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.

$Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL$

Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL

Frederick Locke, MD

April 8th 2022

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

Frederick Locke, MD, and Michael Jain, MD, PhD, on Why Some Patients With Lymphoma Do Not Respond to Cellular Immunotherapy

Frederick Locke, MD;Michael Jain, MD, PhD

March 2nd 2021

CancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.

Investigating CAR T-Cell Therapy in Patients With DLBCL, FL, and Other Lymphomas

Frederick Locke, MD

March 7th 2018

In this interview, Dr. Frederick Locke discusses the promise of CAR T-cell therapy for lymphomas, and how this gene therapy could offer hope for patients who don't respond to standard treatments.

CAR T-Cell Therapy Yields High Response Rate in Aggressive Lymphoma

Frederick Locke, MD

April 7th 2017

This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.